Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Efficacy and Safety of Insulin Aspart Versus Glibenclamide in Type 2 Diabetes

This study has been terminated.
(This trial was terminated due to low recruitment)
Information provided by (Responsible Party):
Novo Nordisk A/S Identifier:
First received: December 20, 2005
Last updated: March 3, 2016
Last verified: March 2016
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: April 2006
  Primary Completion Date: April 2006 (Final data collection date for primary outcome measure)